DK2437726T3 - Formuleringer til behandling af dyb vævssmerte - Google Patents

Formuleringer til behandling af dyb vævssmerte Download PDF

Info

Publication number
DK2437726T3
DK2437726T3 DK10742250.3T DK10742250T DK2437726T3 DK 2437726 T3 DK2437726 T3 DK 2437726T3 DK 10742250 T DK10742250 T DK 10742250T DK 2437726 T3 DK2437726 T3 DK 2437726T3
Authority
DK
Denmark
Prior art keywords
formulation
surfactant
lipid
edta
buffer
Prior art date
Application number
DK10742250.3T
Other languages
English (en)
Inventor
John Charles Mayo
George Langton Iliffe
Ulrich Vierl
Matthias Rother
Original Assignee
Sequessome Tech Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42785828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2437726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sequessome Tech Holdings Limited filed Critical Sequessome Tech Holdings Limited
Application granted granted Critical
Publication of DK2437726T3 publication Critical patent/DK2437726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

1. Vesikulasr formulering til anvendelse i behandlingen af smerte, der hasnger sammen med osteoarthritis, omfattende en eller flere phospholipider og en eller flere ikke-ioniske tensider, og som er fri for ethvert farmaceutisk aktivt stof, der ikke er en lipid eller tensid, hvor formuleringen pafores topisk.
2. Vesikulasr formulering ifolge krav 1 til anvendelse i behandlingen af smerte inklusive dyb vasvssmerte.
3. Vesikulasr formulering ifolge et af de foregaende krav, hvor molforholdet af phospholipid til tensid ligger i omradet fra ca. 1:3 til ca. 30:1, foretrukket ca. 1:1 til ca. 30:1 og mere foretrukket ca. 2:1 til ca. 20:1.
4. Vesikulasr formulering ifolge et af de foregaende krav, hvor formuleringen indeholder 2,0-10,0 v3egt-% phospholipid.
5. Vesikulasr formulering ifolge et af de foregaende krav, hvor den ene eller de flere phospholipider inkluderer phosphatidylcholin.
6. Vesikulasr formulering ifolge et af de foregaende krav, hvor formuleringen indeholder 0,2-5,0 v3egt-% tensid.
7. Vesikulasr formulering ifolge et af de foregaende krav, hvor formuleringen omfatter en eller flere ikke-ioniske tensider udvalgt fra polyoxyethylen-sorbitaner, polyhydroxyethylen-stearater og polyhydroxyethylen-laurylethere.
8. Vesikulasr formulering ifolge et af de foregaende krav, hvor den ene eller flere tensider inkluderer polysorbat 80.
9. Vesikulasr formulering til anvendelse i behandlingen af smerte, der hasnger sammen med osteoarthritis, og som i det vassentlige bestar af en eller flere phospholipider og en eller flere ikke-ioniske tensider i en farmaceutisk acceptabel basrer, hvor formuleringen er topisk pafort.
10. Vesikulasr formulering ifolge krav 10, hvor molforholdet af phospholipid til tensid ligger i omradet fra ca. 1:3 til ca. 30:1, foretrukket ca. 1:1 til ca. 30:1, og mere foretrukket ca. 2:1 til ca. 20:1.
11. Vesikulasr formulering ifolge krav 10 eller krav 11, hvor den ene eller de flere phospholipider inkluderer phosphatidylcholin.
12. Vesikulasr formulering ifolge krav 10, krav 11 eller krav 12, hvor formuleringen omfatter en eller flere ikke-ioniske tensider udvalgt fra polyoxyethylen-sorbitaner, polyhydroxyethylen-stearater og polyhydroxyethylen-laurylethere.
13. Vesikulasr formulering ifolge et af kravene 10 til 13, hvor formuleringen endvidere inkluderer en eller flere buffere, chelatdannere, fugtighedsbevarende midler, smoremidler, antioxidanter, konserveringsmidler, mikrobiocider, antimikrobielle midler, emollienter, cosolventer eller fortykkelsesmidler.
DK10742250.3T 2009-06-03 2010-06-03 Formuleringer til behandling af dyb vævssmerte DK2437726T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18395609P 2009-06-03 2009-06-03
US31447810P 2010-03-16 2010-03-16
US32014810P 2010-04-01 2010-04-01
PCT/IB2010/001557 WO2010140061A2 (en) 2009-06-03 2010-06-03 Formulations for the treatment of deep tissue pain

Publications (1)

Publication Number Publication Date
DK2437726T3 true DK2437726T3 (da) 2018-08-13

Family

ID=42785828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10742250.3T DK2437726T3 (da) 2009-06-03 2010-06-03 Formuleringer til behandling af dyb vævssmerte

Country Status (25)

Country Link
US (2) US20120220669A1 (da)
EP (1) EP2437726B1 (da)
JP (2) JP2012528846A (da)
KR (1) KR20140021950A (da)
CN (4) CN105434354A (da)
AU (1) AU2010255391C1 (da)
BR (1) BRPI1010861A8 (da)
CA (1) CA2764227C (da)
CL (1) CL2011003065A1 (da)
CO (1) CO6480985A2 (da)
DE (1) DE112010001765T5 (da)
DK (1) DK2437726T3 (da)
EA (1) EA029132B1 (da)
ES (1) ES2682075T3 (da)
GB (1) GB2483419B (da)
IL (1) IL216737A (da)
LT (1) LT2437726T (da)
MX (1) MX349417B (da)
MY (1) MY170121A (da)
NZ (1) NZ597419A (da)
PL (1) PL2437726T3 (da)
PT (1) PT2437726T (da)
SG (1) SG176297A1 (da)
WO (1) WO2010140061A2 (da)
ZA (1) ZA201200017B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486371A (en) * 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
KR102325654B1 (ko) * 2013-07-31 2021-11-12 시퀘솜 네크놀로지 홀딩스 리미티드 소포체
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
US20190167588A1 (en) 2015-06-30 2019-06-06 Sequessome Technology Holdings Limited Blended formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
CN114507408A (zh) * 2022-03-02 2022-05-17 陕西科技大学 一种低摩擦、模量可调的物理水凝胶及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
ES2107668T3 (es) * 1992-07-08 1997-12-01 Dianorm G Maierhofer Gmbh Liposomas, procedimiento para su preparacion y su uso en la elaboracion de un medicamento.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
CN1322129A (zh) * 1998-09-01 2001-11-14 伊迪亚股份公司 带电穿透剂通过屏障的电控转运
RU2207844C2 (ru) * 1998-12-23 2003-07-10 Идеа Аг. УСОВЕРШЕНСТВОВАННЫЙ ПРЕПАРАТ ДЛЯ МЕСТНОГО НЕИНВАЗИВНОГО ПРИМЕНЕНИЯ in vivo
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
EP1230917A1 (de) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
EP1551370B1 (en) * 2002-10-11 2007-12-19 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
JP2004131432A (ja) * 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
CA2524478A1 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
BRPI0412882A (pt) * 2003-07-21 2006-10-03 Vasogen Ireland Ltd uso de uma quantidade de corpos farmaceuticamente aceitáveis que portam um número eficaz de grupos contendo fosfato
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
EP2079442B1 (en) * 2006-09-28 2016-07-27 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication

Also Published As

Publication number Publication date
GB2483419B (en) 2015-04-08
CA2764227A1 (en) 2010-12-09
US20160175448A1 (en) 2016-06-23
MY170121A (en) 2019-07-05
WO2010140061A3 (en) 2011-07-28
KR20140021950A (ko) 2014-02-21
EA029132B1 (ru) 2018-02-28
CN102639113A (zh) 2012-08-15
LT2437726T (lt) 2018-09-10
EP2437726A2 (en) 2012-04-11
EP2437726B1 (en) 2018-05-16
GB201122433D0 (en) 2012-02-08
WO2010140061A2 (en) 2010-12-09
CO6480985A2 (es) 2012-07-16
CN105434353A (zh) 2016-03-30
BRPI1010861A8 (pt) 2023-01-24
GB2483419A (en) 2012-03-07
JP2012528846A (ja) 2012-11-15
IL216737A (en) 2016-09-29
BRPI1010861A2 (pt) 2018-06-12
PT2437726T (pt) 2018-08-10
CL2011003065A1 (es) 2012-08-31
CN105434354A (zh) 2016-03-30
DE112010001765T5 (de) 2012-12-27
NZ597419A (en) 2014-01-31
AU2010255391C1 (en) 2016-10-27
EA201190344A1 (ru) 2012-09-28
CA2764227C (en) 2016-12-06
MX349417B (es) 2017-07-28
MX2011012754A (es) 2012-07-25
ES2682075T3 (es) 2018-09-18
IL216737A0 (en) 2012-02-29
SG176297A1 (en) 2012-01-30
JP2015193629A (ja) 2015-11-05
CN105434329A (zh) 2016-03-30
ZA201200017B (en) 2019-01-30
PL2437726T3 (pl) 2018-12-31
AU2010255391A1 (en) 2012-02-02
AU2010255391B2 (en) 2016-06-02
US20120220669A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
DK2437726T3 (da) Formuleringer til behandling af dyb vævssmerte
US9452179B2 (en) Vesicular formulations
US20170128473A1 (en) Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint
US9555051B2 (en) Vesicular formulations
EP2849721A1 (en) Vesicular formulations, uses and methods
US20150132349A1 (en) Vesicular Formulations, Kits and Uses
HK1164156B (en) Formulations for the treatment of deep tissue pain
HK1164156A (en) Formulations for the treatment of deep tissue pain
AU2015202217A1 (en) Vesicular formulations